AXOGEN ($NASDAQ:AXGN) reported total revenue of USD 38.2 million for the second quarter ending June 30 2023, which represented a 10.8% increase from the same period a year earlier. Net income, however, decreased by -1 million to -6.7 million in comparison to the second quarter of FY2022.
Analysis – Axogen Intrinsic Value
GoodWhale conducted an extensive analysis of AXOGEN‘s wellbeing, utilizing our proprietary Valuation Line. After careful consideration, we concluded that the intrinsic value of AXOGEN share is around $13.9. However, the current market price for AXOGEN stock is traded at $8.3, which is undervalued by 40.5%. This presents an incredible opportunity for investors to purchase AXOGEN stock at a discounted price. The analysis conducted by GoodWhale can help inform investors of the potential value of AXOGEN and the potential for lucrative returns by investing in the company. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Axogen. AXOGEN_Reports_10.8_Increase_in_Revenue_for_Q2_2023_with_USD_38.2_Million_Total”>More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Axogen. AXOGEN_Reports_10.8_Increase_in_Revenue_for_Q2_2023_with_USD_38.2_Million_Total”>More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Axogen. AXOGEN_Reports_10.8_Increase_in_Revenue_for_Q2_2023_with_USD_38.2_Million_Total”>More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Axogen are shown below. AXOGEN_Reports_10.8_Increase_in_Revenue_for_Q2_2023_with_USD_38.2_Million_Total”>More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
The medical device industry is extremely competitive, with companies constantly vying for market share. This is especially true in the area of nerve repair, where Axogen Inc faces stiff competition from iRadimed Corp, Neovasc Inc, and PROCEPT BioRobotics Corp. While each company has its own unique product offerings, they all share one common goal: to provide the best possible products and services to their customers.
Radimed Corp is a medical device company that manufactures and markets products for the diagnosis and treatment of cardiovascular diseases. The company has a market cap of $355.34 million and a return on equity of 13.08%. Radimed’s products are used by cardiologists, radiologists, and vascular surgeons to diagnose and treat cardiovascular diseases. The company’s products include coronary stents, balloon catheters, and other devices.
Neovasc Inc is a medical device company that develops, manufactures and markets cardiovascular products. Its products include the Tiara technology for the treatment of mitral valve disease and the Reducer device for the treatment of refractory angina. The company’s products are sold in the United States, Europe, Canada and Israel.
– PROCEPT BioRobotics Corp ($NASDAQ:PRCT)
PROCEPT BioRobotics Corp is a medical device company that focuses on the development of minimally invasive surgical solutions. The company has a market capitalization of 1.99 billion as of 2022 and a return on equity of -16.02%. The company’s products include the CorPath GRX System, which is a robot-assisted system that is used in interventional cardiology procedures, and the CorPath Vascular Stent System, which is used in the treatment of peripheral artery disease.
AXOGEN‘s second quarter ending June 30 2023 saw total revenue of USD 38.2 million, a 10.8% increase from the same period in FY2022. Net income, however, decreased by -1 million, resulting in a negative net income of -6.7 million. For investors, this indicates a mixed performance, with revenue improving but net income decreasing when compared to the prior year. Despite the decrease in net income, AXOGEN still remains a viable option for investors looking for potential returns.